Time to diagnosis of retinoblastoma in Latin America: A systematic review
- PMID: 31014139
- DOI: 10.1080/08880018.2019.1605432
Time to diagnosis of retinoblastoma in Latin America: A systematic review
Abstract
Retinoblastoma (RB) is the most common intraocular tumor of childhood. In low income countries, Time to diagnosis (TTD: interval between first symptom and diagnosis) has been associated with extraocular disease, metastasis and mortality. However, the relationship between TTD and prognosis is complex and not simply a linear correlation, particularly if TTD is <6 months. This systematic review aims to identify studies reporting TTD of retinoblastoma in Latin America, highlighting factors affecting TTD, alongside proposals and initiatives to obtain shorter intervals. The review also aims to discuss the methodology linked to cancer pathways studies. The study respected PRISMA recommendations, was registered on Prospero, an international database for systematic review registries under number CRD42017076777. MEDLINE/PUBMED, LILACS and SCIELO databases were searched. Studies from Latin America and the Caribbean, published between 1997 and 2017, reporting TTD and age at diagnosis of patients with retinoblastoma were selected. Nine studies were selected, concerning 1560 patients from Argentina, Brazil, Chile, Honduras, Mexico and Peru. The median TTD ranged from 3 to 5 months and the median age at diagnosis ranged from 16.5 to 22.2 months. A prolonged TTD was observed and was associated to damaging results on retinoblastoma outcomes, particularly increasing extraocular disease, and mortality rates. Methodological heterogeneity was observed and reiterates the importance of standardization of TTD studies, allowing more reliable comparisons and greater knowledge about retinoblastoma pathways before diagnosis. Reports on successful initiatives against delayed diagnosis were scarce, emphasizing a need for further studies.
Keywords: Childhood cancer; delayed diagnosis; early detection of cancer; late diagnosis; retinoblastoma.
Comment in
-
Retinoblastoma in Low- and Middle-Income Countries.Pediatr Hematol Oncol. 2019 Mar;36(2):53-54. doi: 10.1080/08880018.2019.1624903. Pediatr Hematol Oncol. 2019. PMID: 31195906 No abstract available.
Similar articles
-
[Problematic of the management of childhood cancer: experience of retinoblastoma in Lubumbashi (DR Congo) and the importance of early diagnosis].Pan Afr Med J. 2013;14:64. doi: 10.11604/pamj.2013.14.64.2342. Epub 2013 Feb 14. Pan Afr Med J. 2013. PMID: 23565311 Free PMC article. French. No abstract available.
-
Retinoblastoma referral patterns in Saudi Arabia.Ophthalmic Epidemiol. 1996 Mar;3(1):35-46. doi: 10.3109/09286589609071599. Ophthalmic Epidemiol. 1996. PMID: 8705872
-
Retinoblastoma in a pediatric oncology reference center in Southern Brazil.BMC Pediatr. 2016 Apr 3;16:48. doi: 10.1186/s12887-016-0579-9. BMC Pediatr. 2016. PMID: 27038613 Free PMC article.
-
[Toward a model of communications in public health in Latin America and the Caribbean].Rev Panam Salud Publica. 2005 Dec;18(6):427-38. doi: 10.1590/s1020-49892005001000006. Rev Panam Salud Publica. 2005. PMID: 16536929 Review. Spanish.
-
[Retinoblastoma: review of 19 cases].An Esp Pediatr. 1991 Feb;34(2):107-10. An Esp Pediatr. 1991. PMID: 2042802 Review. Spanish.
Cited by
-
Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.Molecules. 2024 May 11;29(10):2263. doi: 10.3390/molecules29102263. Molecules. 2024. PMID: 38792122 Free PMC article. Review.
-
Anti-proliferation and apoptosis-inducing effects of sodium aescinate on retinoblastoma Y79 cells.Int J Ophthalmol. 2020 Oct 18;13(10):1546-1553. doi: 10.18240/ijo.2020.10.06. eCollection 2020. Int J Ophthalmol. 2020. PMID: 33078103 Free PMC article.
-
Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.Invest Ophthalmol Vis Sci. 2023 Dec 1;64(15):27. doi: 10.1167/iovs.64.15.27. Invest Ophthalmol Vis Sci. 2023. PMID: 38117242 Free PMC article.
-
TRIM59 Promotes Retinoblastoma Progression by Activating the p38-MAPK Signaling Pathway.Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):2. doi: 10.1167/iovs.61.10.2. Invest Ophthalmol Vis Sci. 2020. PMID: 32744597 Free PMC article.
-
The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses.Elife. 2023 Jan 31;12:e81354. doi: 10.7554/eLife.81354. Elife. 2023. PMID: 36718985 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials